Submission Details
| 510(k) Number | K232991 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | September 22, 2023 |
| Decision Date | August 28, 2024 |
| Days to Decision | 341 days |
| Submission Type | Traditional |
| Review Panel | Neurology (NE) |
| Summary | Summary PDF |
K232991 is an FDA 510(k) clearance for the BT-1000, a Transcutaneous Nerve Stimulator For Adhd (Class II — Special Controls, product code QGL), submitted by Bistos Co., Ltd. (Gyeonggi, KR). The FDA issued a Cleared decision on August 28, 2024, 341 days after receiving the submission on September 22, 2023. This device falls under the Neurology review panel. Regulated under 21 CFR 882.5898.
| 510(k) Number | K232991 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | September 22, 2023 |
| Decision Date | August 28, 2024 |
| Days to Decision | 341 days |
| Submission Type | Traditional |
| Review Panel | Neurology (NE) |
| Summary | Summary PDF |
| Product Code | QGL — Transcutaneous Nerve Stimulator For Adhd |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 882.5898 |
| Definition | A Transcutaneous Electrical Nerve Stimulator For Attention Deficit Hyperactivity Disorder (adhd) Is A Prescription Device That Stimulates Transcutaneously Or Percutaneously Through Electrodes Placed On The Forehead. |